Méher Ben Abdelghani
A5005765894- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Colorectal and Anal Carcinomas
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Colorectal Cancer Surgical Treatments
- Esophageal Cancer Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Metastasis and carcinoma case studies
- Lung Cancer Diagnosis and Treatment
- Esophageal and GI Pathology
- Radiomics and Machine Learning in Medical Imaging
- Diagnosis and treatment of tuberculosis
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Nutrition and Health in Aging
Institut de Cancérologie Strasbourg
2011-2024
Pôle de Recherche pour l'Organisation et la Diffusion de l'Information Géographique
2023
Inserm
2018
Levi Strauss (United States)
2016-2018
Centre Hospitalier Universitaire Dijon Bourgogne
2018
Reutlingen University
2013
Eurométropole de Strasbourg
2011
Hôpitaux Universitaires de Strasbourg
2003-2005
Univerzitná Nemocnica Louisa Pasteura
2003
Hôpital d'Hautepierre
2000
Among patients with metastatic pancreatic cancer, combination chemotherapy fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy safety of a modified FOLFIRINOX regimen as adjuvant therapy in resected cancer.
Background Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain common. We aimed to assess whether administering neoadjuvant before preoperative chemoradiotherapy could reduce the risk recurrences. Methods did a phase 3, open-label, multicentre, randomised trial at 35 hospitals in France. Eligible patients were adults aged 18–75 years had newly diagnosed, biopsy-proven, adenocarcinoma...
Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment modified FOLFIRINOX vs gemcitabine in patients resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase was conducted 77 hospitals France Canada included aged 18 to 79 histologically confirmed adenocarcinoma who had undergone...
LBA4001 Background: FOLFIRINOX is more effective than gem as first-line treatment in metastatic pancreatic cancer for patients (pts) with good performance status. This trial assessed the benefit of mFOLFIRINOX adjuvant setting. Methods: PRODIGE 24/CCTG PA.6 a phase III multicenter, randomized clinical trial. Pts aged 18-79 years histologically proven ductal adenocarcinomas, 21-84 days after R0 or R1 resection, WHO PS ≤1, adequate hematologic and renal function, no cardiac ischemia, were...
The objective of this study was to build and validate a radiomic signature predict early poor outcome using baseline 2-month evaluation CT compare it the RECIST1·1 morphological criteria defined by changes in homogeneity borders.This is an ancillary from PRODIGE-9 multicentre prospective for which 491 patients with metastatic colorectal cancer (mCRC) treated 5-fluorouracil, leucovorin irinotecan (FOLFIRI) bevacizumab had been analysed. In 230 patients, computed texture analysis performed on...
225 Background: No standard post-surgery adjuvant treatment is currently recommended in localized biliary tract cancer (BTC). Gemcitabine combined with platinum the chemotherapy for advanced BTC. The aim of this phase III randomized trial was to assess whether GEMOX would increase relapse-free survival (RFS) while maintaining health-related quality life (HrQoL). Methods: We performed a multicenter trial. Patients were randomized, within 3 months R0 or R1 resection BTC (intra-hepatic,...
Background Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. Material Methods A joint analysis two multicentre observational retrospective cohort studies independently conducted France Italy was performed. All consecutive FGFR2-positive affected by treated as second- further line systemic treatment clinical practice, within outside...
Only 1 randomized clinical trial has shown the superiority of immune checkpoint inhibitors in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) first-line setting.To determine whether avelumab (an anti-programmed cell death ligand antibody) improves progression-free survival (PFS) compared standard second-line chemotherapy dMMR/MSI mCRC.The SAMCO-PRODIGE 54 is a national open-label phase 2 that was conducted from April...
After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting gemcitabine (GEM)-based regimens or the modified FOLFIRINOX (mFFX) regimen. While mFFX regimen has been shown to be more effective than GEM-based regimens, it is also associated higher toxicity. Current treatment decisions based on patient performance status rather molecular characteristics tumor. To address this gap, goal study was develop...
One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared CT other advanced dMMR/MSI-H digestive tumors.
Identify prognostic factors for survival and patterns of treatment failure after definitive radiochemotherapy esophageal cancer. Between 2003 2006, 143 patients with squamous cell carcinoma adenocarcinoma the esophagus were retrospectively reviewed. Median age was 65 years (42–81). radiation dose 62.5 Gy (38–72) 1.8–2 fraction. follow-up 20.8 months (2.8–92.4). Three 5-year local recurrence-free rates 58.3% 50.9%. In univariate analysis, traversable stricture a factor. Three, locoregional...
Importance The optimal maintenance strategy after induction chemotherapy with anti–epidermal growth factor receptor antibody for patients RAS wild-type metastatic colorectal cancer (mCRC) remains to be debated. Objective To evaluate the efficacy and safety of therapy single-agent cetuximab FOLFIRI (leucovorin [folinic acid], fluorouracil, irinotecan) plus therapy. Design, Setting, Participants TIME (Treatment After Irinotecan-Based Frontline Therapy: Maintenance With Erbitux]) (PRODIGE 28...
// Juliette Palle 1 , David Tougeron 2 Astrid Pozet 3 Emilie Soularue 4 Pascal Artru 5 Florence Leroy 6 Olivier Dubreuil 7 Matthieu Sarabi 8 Nicolas Williet 9 Sylvain Manfredi 10 Jerome Martin-Babau 11 Christine Rebischung 12 Meher Ben Abdelghani 13 Ludovic Evesque 14 Johann Dreanic 15 Vincent Hautefeuille 16 Samy Louafi 17 Sefrioui 18 Francesco Savinelli 19 May Mabro 20 Benoit Rousseau 21 Cédric Lecaille 22 Bouché 23 Christophe Louvet 24 Thierry Lecomte 25 Franck Bonnetain Julien Taieb 1,...
BackgroundImmune checkpoint inhibitors (ICI) targeting Programmed death-1 (PD-1) have shown their efficacy in advanced MSI/dMMR (microsatellite instability/deficient mismatch repair) tumors. The status predicts clinical response to ICI. promising results evaluating ICI localized tumors neoadjuvant setting need be confirmed solid aim of the IMHOTEP trial is assess anti-PD-1 treatment regarding pathological complete rate.MethodsThis study a prospective, multicenter, phase II including 120...
GemPred, a transcriptomic signature predictive of the efficacy adjuvant gemcitabine (GEM), was developed from cell lines and organoids validated retrospectively. The phase III PRODIGE-24/CCTG PA6 trial has demonstrated superiority modified folinic acid, fluorouracil, irinotecan, oxaliplatin (mFOLFIRINOX) over GEM as therapy in patients with resected pancreatic ductal adenocarcinoma at expense higher toxicity. We evaluated potential value GemPred this population.
4019 Background: The incidence of SRC gastric cancers is markedly increasing in Western countries. may harbor intrinsic resistance to chemotherapy (CTx) leaving many clinicians unsure the benefits delaying surgery pursue a neoadjuvant approach. primary objective this study was assess whether upfront plus adjuvant CTx would provide enough survival benefit for phase III trial when compared perioperative CTx. Methods: Patients with stage IB-III cancer were randomly assigned receive (epirubicin,...
673 Background: Maintenance treatments in m-PDAC patients (pts) after FFX induction is discussed. We assessed the efficacy of genetic-driven maintenance pts with controlled disease. Methods: In this multicenter, open-label, phase II study, PS 0-1 histologically confirmed 4 months (mo) mFFX received a genetically-driven therapy (centralized analysis): BRCAness - olaparib 300 mgx2/d (Arm A); no BRCAness, but KRAS mutation randomization (2:1) to S+D (1500 mg IV q4w + 75 PO BID; Arm B) or...